吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究  

Combined gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer.

作　　者：冷嘉兴[1] 徐建忠[1] 孙毅[1] 徐珍[1] 孔颖泽[1] 

机构地区：[1]常州肿瘤医院肿瘤内科,江苏常州213001

出　　处：《现代肿瘤医学》2005年第3期393-394,共2页Journal of Modern Oncology

摘　　要：目的评价吉西他滨(gemcitabine)联合顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法选择经病理证实的晚期非小细胞肺癌41例住院患者采用GP方案行静脉化疗,具体为Gemcitabine1250mg/m2d1、d8,DDP30mg/m2d1～d3,21天重复,至少使用2周期以上。结果完全缓解(CR)4.9%(2/41),部分缓解(PR)43.9%(18/41),稳定(SD)34.1%(14/41),进展(PD)17.0%(7/41),总有效率(RR)48.8%;肿瘤控制率(CR+PR+SD)为82.19%;中位缓解期7.1m,中位生存期11m(4.5～20m);毒副反应以白细胞及血小板下降、消化道反应、乏力为常见,均可耐受,无化疗相关死亡。结论吉西他滨联合顺铂对晚期非小细胞肺癌有较好疗效,毒副反应可以耐受,值得临床推广。Objective To evaluate the clinical efficacy and toxicity of advanced non-small cell lung cancer (NSCLC) treated by combined gemcitabine and cisplatin. Methods Forty-one patients with advancd NSCLC enrolled in alloted to the study. The patients received gemcitabine 1250mg/m^2 on d1, d8 and cisplatin 30mg/ m^2 on d1~d3 in the 21-day cycle. Results An objective response was obtained in 48.8%(RR 20/41) of patients (2 CR and 18 PR), whereas 14 patients had setable disease and 7patients showed progressive disease. The cancer control rate was 82.9%(CR+PR+NC). The median response duration was 7.1 months and the median survival duration was 11.0 months. The main toxicities were leukopenia, thrombocytopenia,gastro-intertinal reaction and weakness. Conclusion The combination of gemcitabine and cisplatin, being feasible and well-tolerated, should be taken as an energetic scheme in the treatment of advanced NSCLC.

关 键 词：非小细胞肺癌 药物治疗 吉西他滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]